1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

AstraZeneca’s IBD Hopes Deflated Amid Evolving Market And Pipeline Competition

Says Goodbye To Brazikumab

 
• By Ayisha Sharma

The major’s attempt to break into Crohn’s disease and ulcerative colitis has been cut short as a highly competitive market and pipeline, intensified by the entrance of biosimilars, renders further development of brazikumab impractical.  

Key Takeaways:

  • Brazikumab is being dropped due to the evolving competitive landscape and delays to its timeline.

AstraZeneca PLC has discontinued its anti-IL-23 monoclonal antibody, brazikumab, for inflammatory bowel diseases (IBD) as the market and pipeline become increasingly crowded and following unavoidable delays to the asset’s planned timeline.

The development plan for brazikumab comprised the Phase IIb/III INTREPID trial in Crohn’s disease and the Phase II EXPEDITION trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 
• By Alaric DeArment

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.